AOP Health’s decision to run its rare disease and intensive care operations on Veeva Systems (VEEV) cloud platforms highlights how deeply Veeva’s software can be embedded across clinical, regulatory, safety, and commercial workflows.
See our latest analysis for Veeva Systems.
Even with news like the AOP Health rollout highlighting real world use of its platforms, Veeva’s share price tells a mixed story. A 7 day share price return of 2.9% is set against a 1 year total shareholder return decline of 22.26% and a 5 year total shareholder return decline of 27.65%, which points to longer term momentum fading.
If you are weighing Veeva against other opportunities in healthcare technology, it can be useful to see how peers are priced and growing by scanning 35 healthcare AI stocks
With shares down over 22% on a 1 year view but trading at a discount to some analyst targets and intrinsic estimates, should you see Veeva as undervalued at this level, or is the market already pricing in future growth?
Most Popular Narrative: 32.1% Undervalued
Veeva Systems’ most followed narrative puts fair value at $270.93 versus a last close of $184.07, which raises a clear valuation gap for investors to unpack.
The resolution of the long-standing dispute with IQVIA removes critical data interoperability barriers, enabling Veeva to fully integrate industry-leading datasets into its Commercial Cloud, which should materially expand its addressable market, improve product adoption across multiple commercial applications, and accelerate top-line revenue growth over the next several years.
Curious what sits behind that valuation gap? The narrative leans heavily on compounded revenue gains, firmer margins and a future earnings multiple that must hold up over time.
Result: Fair Value of $270.93 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the story could change quickly if large pharma customers slow adoption of new Veeva products, or if heavyweight competitors like Salesforce and Microsoft win key CRM share.
Find out about the key risks to this Veeva Systems narrative.
Another View: Valuation Through Earnings Multiples
The narrative fair value of $270.93 implies upside from the current $184.07, but the current P/E of 33.3x muddies the picture. It sits above the estimated fair ratio of 31x and above both the Global Healthcare Services average of 28.4x and peer average of 28.9x, which suggests the market already prices in a lot of optimism. So is this a margin of safety or a premium that needs more proof?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
All this mixed sentiment around valuation and growth potential only matters if you weigh it against the underlying rewards and risks yourself. If you want a quick way to see what the market is optimistic about before making your own call, start with the 4 key rewards.
Looking for more investment ideas?
If Veeva has sharpened your thinking, do not stop there. Widening your opportunity set can help you spot setups that others might overlook.
- Target potential mispricing by scanning companies that currently screen as 52 high quality undervalued stocks before attention shifts and the gap closes.
- Prioritise resilience by checking out solid balance sheet and fundamentals stocks screener (39 results) and focus on businesses with financial footing that may better handle shocks.
- Get ahead of the crowd by reviewing a screener containing 25 high quality undiscovered gems that the wider market may not be watching yet.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com